Axial Biotherapeutics Co-founder Sarkis Mazmanian to Give Keynote Speech at the Microbiome in Health and Disease Keystone Symposium
BOSTON and Pasadena, Calif., February 3, 2017 – Axial Biotherapeutics, a biotechnology company building a unique class of microbial-targeted CNS therapeutics today announced that its Co-founder and California Institute of Technology (Caltech) Professor, Sarkis Mazmanian, Ph.D., will be featured as the keynote speaker at the Microbiome in Health and Disease Keystone Symposium held in Keystone, Colorado, February 5-9, 2017. The keynote titled, “The Gut-Microbiome-Brain Connection in Neurological Diseases,” will be held on Monday, February 6, 8:00 am MT / 10:00 am ET.
Dr. Mazmanian is a leader in the field of interactions between the gut microbiome and the brain as it relates to neurological disorders and Axial has licensed exclusive, worldwide rights to related intellectual property from the Mazmanian Laboratory at Caltech. Dr. Mazmanian has published his groundbreaking research in journals that include Nature, Science and Cell. Most recently, the Mazmanian Laboratory discovered a novel biological link between the gut microbiome and Parkinson’s disease (PD) published in Cell in December 2016. Axial’s focus will be to translate these discoveries into a unique class of microbial-targeted biotherapeutics that could become breakthrough therapies for a variety of neurological diseases and disorders, including Autism Spectrum Disorders (ASD) and PD.
About Axial Biotherapeutics
Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders. www.axialbiotherapeutics.com
MacDougall Biomedical Communications
Kari Watson or Stephanie May, Ph.D.
Direct: +1 781 235 3060 or +49 89 24243494
email@example.com or firstname.lastname@example.org